Cardiff Oncology Analyst Ratings
Cardiff Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 728.03% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/09/2023 | 791.72% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 03/29/2023 | 855.41% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/07/2023 | 855.41% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 09/16/2022 | 791.72% | HC Wainwright & Co. | $22 → $14 | Maintains | Buy |
| 09/13/2022 | 218.47% | Piper Sandler | $7 → $5 | Maintains | Overweight |
| 08/29/2022 | 282.17% | Baird | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 1301.27% | HC Wainwright & Co. | $25 → $22 | Maintains | Buy |
| 02/28/2022 | 1492.36% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 12/08/2021 | 1110.19% | Baird | → $19 | Initiates Coverage On | → Outperform |
| 08/10/2021 | 1556.05% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 05/10/2021 | 1492.36% | HC Wainwright & Co. | $27 → $25 | Maintains | Buy |
| 10/22/2020 | 1619.75% | HC Wainwright & Co. | → $27 | Initiates Coverage On | → Buy |
| 10/08/2020 | 1492.36% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 09/18/2020 | 791.72% | Maxim Group | $6 → $14 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/08/2023 | 728.03% | HC Wainwright & Co. | 14 美元 → 13 美元 | 维护 | 购买 |
| 05/09/2023 | 791.72% | HC Wainwright & Co. | 15 美元 → 14 美元 | 维护 | 购买 |
| 03/29/2023 | 855.41% | HC Wainwright & Co. | → 15 美元 | 重申 | → 购买 |
| 03/07/2023 | 855.41% | HC Wainwright & Co. | 14 美元 → 15 美元 | 维护 | 购买 |
| 2022 年 9 月 16 日 | 791.72% | HC Wainwright & Co. | 22 美元 → 14 美元 | 维护 | 购买 |
| 09/13/2022 | 218.47% | 派珀·桑德勒 | 7 美元 → 5 美元 | 维护 | 超重 |
| 08/29/2022 | 282.17% | 贝尔德 | 9 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 05/09/2022 | 1301.27% | HC Wainwright & Co. | 25 美元 → 22 美元 | 维护 | 购买 |
| 02/28/2022 | 1492.36% | HC Wainwright & Co. | 26 美元 → 25 美元 | 维护 | 购买 |
| 2021 年 8 月 12 日 | 1110.19% | 贝尔德 | → 19 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 2021 年 10 月 8 日 | 1556.05% | HC Wainwright & Co. | 25 美元 → 26 美元 | 维护 | 购买 |
| 2021 年 10 月 5 日 | 1492.36% | HC Wainwright & Co. | 27 美元 → 25 美元 | 维护 | 购买 |
| 2020 年 10 月 22 日 | 1619.75% | HC Wainwright & Co. | → 27 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 8 月 10 日 | 1492.36% | 派珀·桑德勒 | → 25 美元 | 启动覆盖开启 | → 超重 |
| 09/18/2020 | 791.72% | Maxim 集团 | 6 美元 → 14 美元 | 维护 | 购买 |
What is the target price for Cardiff Oncology (CRDF)?
加的夫肿瘤学（CRDF）的目标价格是多少？
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $13.00 expecting CRDF to rise to within 12 months (a possible 728.03% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月8日公布了加的夫肿瘤学（纳斯达克股票代码：CRDF）的最新目标股价。这家分析公司将目标股价定为13.00美元，预计CRDF将在12个月内升至12个月内（可能上涨728.03％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
分析师对加的夫肿瘤学（CRDF）的最新评级是多少？
The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
加的夫肿瘤学（纳斯达克股票代码：CRDF）的最新分析师评级由HC Wainwright & Co. 提供，Cardiff Oncology 维持买入评级。
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Cardiff Oncology（CRDF）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析师在进行了广泛的研究，包括浏览公开财务报表、与Cardiff Oncology的高管和客户交谈以及听取财报电话会议后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Cardiff Oncology 的最后评级是在2023年8月8日提交的，因此您应该预计下一个评级将在2024年8月8日左右公布。
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
分析师对加的夫肿瘤学 (CRDF) 的评级是否正确？
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $14.00 to $13.00. The current price Cardiff Oncology (CRDF) is trading at is $1.57, which is out of the analyst's predicted range.
虽然评级是主观的，将会发生变化，但最新的加的夫肿瘤学（CRDF）评级维持不变，目标股价为14.00美元至13.00美元。Cardiff Oncology（CRDF）目前的交易价格为1.57美元，超出了分析师的预测区间。